Therapeutic cancer vaccines
The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …
Harnessing the immune system in acute myeloid leukaemia
Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of
immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction …
immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction …
Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies
A Di Stasi, AM Jimenez, K Minagawa… - Frontiers in …, 2015 - frontiersin.org
We performed a systematic review of data from nine clinical trials of WT1 peptide vaccination
in patients with myelodysplastic syndromes and/or acute myeloid leukemia (MDS/AML) …
in patients with myelodysplastic syndromes and/or acute myeloid leukemia (MDS/AML) …
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency
MC Lahman, TM Schmitt, KG Paulson… - Science translational …, 2022 - science.org
Designing effective antileukemic immunotherapy will require understanding mechanisms
underlying tumor control or resistance. Here, we report a mechanism of escape from …
underlying tumor control or resistance. Here, we report a mechanism of escape from …
Wilms' tumor gene 1 (WT1) peptide vaccine therapy for hematological malignancies: from CTL epitope identification to recent progress in clinical studies including a …
Y Oka, A Tsuboi, J Nakata, S Nishida… - Oncology Research …, 2017 - karger.com
The identification of human Wilms' tumor gene 1 (WT1) protein-derived cytotoxic T
lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in …
lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in …
Current strategies in immunotherapy for acute myeloid leukemia
FS Lichtenegger, FM Schnorfeil, W Hiddemann… - …, 2013 - Taylor & Francis
The prognosis of acute myeloid leukemia, particularly when associated with adverse
chromosomal or molecular aberrations, is poor due to a high relapse rate after induction …
chromosomal or molecular aberrations, is poor due to a high relapse rate after induction …
Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell …
T Ishikawa, N Fujii, M Imada, M Aoe, Y Meguri… - Cytotherapy, 2017 - Elsevier
Abstract Background Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has
recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia …
recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia …
CD4+ and CD8+ T-cell reactions against leukemia-associated-or minor-histocompatibility-antigens in AML-patients after allogeneic SCT
B Steger, S Milosevic, G Doessinger, S Reuther… - Immunobiology, 2014 - Elsevier
T-cells play an important role in the remission-maintenance in AML-patients (pts) after SCT,
however the role of LAA-(WT1, PR1, PRAME) or minor-histocompatibility (mHag, HA1) …
however the role of LAA-(WT1, PR1, PRAME) or minor-histocompatibility (mHag, HA1) …
A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia
Y Kobayashi, T Sakura, S Miyawaki, K Toga… - Cancer Immunology …, 2017 - Springer
Abstract Wilms' tumor 1 (WT1) is a promising target of new immunotherapies for acute
myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived …
myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived …
Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients
GI Mossallam, TM Abdel Hamid, HK Mahmoud - Hematology, 2013 - Taylor & Francis
Abstract Background Wilms' tumor (WT1) gene overexpression has been reported in the
majority of acute myeloid leukemia (AML) patients at diagnosis and has been evaluated as …
majority of acute myeloid leukemia (AML) patients at diagnosis and has been evaluated as …